048530 — iNtRON Biotechnology Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapSucker Stock

Annual cashflow statement for iNtRON Biotechnology, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	14,948	9,728	5,712	-9,695	-2,591
Depreciation
Amortisation
Non-Cash Items	20.6	2,283	-4,382	6,792	-2,482
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-9,407	2,925	3,080	4,109	2,909
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Other Operating Cash Flow
Cash from Operating Activities	7,131	16,473	5,977	3,118	-138
Capital Expenditures	-6,070	-3,494	-2,617	-9,552	-1,186
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	8,427	-37,784	-43,605	61,704	4,256
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	2,356	-41,278	-46,221	52,153	3,070
Financing Cash Flow Items	-56.6	-0.014	-0.01	—	—
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-2,066	39,750	-9,191	-40,168	-9,818
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	6,514	15,243	-49,359	15,175	-6,628